Synthesis and antineoplastic activity of 2-alkylaminoethyl derivatives of various steroidal oximes

European Journal of Medicinal Chemistry

Volumn 38, Issue 11-12, 2003, Pages 1025-1034

  Jindal, Dharam Paul ^a   Chattopadhaya, Raja ^a   Guleria, Sheetal ^a   Gupta, Ranju ^a  

^a PANJAB UNIVERSITY   (India)

Author keywords

6 hydroxiimino derivatives; 60 cell line; Alkylation; Antineoplastic activity; Hollow fiber assay; Steroidal oximes and oxime ethers; Tamoxifen

Indexed keywords

17ALPHA ETHYNYL 3 [2 (2 DIETHYLAMINOETHYL)]OXIMINO 4 ANDROSTEN 17BETA OL; 17ALPHA ETHYNYL 3 [2 (2 PIPERIDINOETHYL)]OXIMINO 4 ANDROSTEN 17BETA OL; 17ALPHA ETHYNYL 3 [2 (2 PYRROLIDINOETHYL)]OXIMINO 4 ANDROSTEN 17BETA OL; 2 (2 DIETHYLAMINOETHYL)OXIMINO 3 METHOXY 1,3,5(10) ESTRATRIENE; 2 (2 PYRROLIDINOETHYL)OXIMINO 3 METHOXY 1,3,5(10) ESTRATRIENE; ALKYL GROUP; ANDROSTANE DERIVATIVE; ANTINEOPLASTIC AGENT; CHLORIDE; ESTRANE DERIVATIVE; ETHER DERIVATIVE; HALIDE; OXIME DERIVATIVE; STEROID; UNCLASSIFIED DRUG;

ALKYLATION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CENTER; CONTROLLED STUDY; DRUG SCREENING; DRUG SYNTHESIS; HOLLOW FIBER; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; TUMOR CELL LINE; UNITED STATES;

EID: 0345306221     PISSN: 02235234     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejmech.2003.09.002     Document Type: Article

References (22)

1. Tomera J.F. Drugs Today. 30:1994;565-574.
2. Grunfeld E.A., Ramirez A.J., Hunter M.S., Richards M.A. Br. J. Cancer. 86:2002;1373-1378.
3. Peto R., Boreham J., Clarke M., Davies C., Beral V. Lancet. 355:2000;1822.
4. Cole P.A., Robinson C.H. J. Med. Chem. 33:1990;2933-2942.
5. Njar V.C.O., Brodie A.M.H. Drugs. 58:1999;233-255.
6. Goss P.E., Gwyn K.M.E.H. J. Clin. Oncol. 12:1994;2460-2470.
7. O'Reilly J.M., Bruggemeier R.W. Curr. Med. Chem. 3:1996;11-22.
8. Foster A.B., Jarman M., Leung C.-S., Rowlands M.G., Taylors G.N., Plevey R.G., Sampson R. J. Med. Chem. 28:1985;200-204.
9. Buzdar A.U. Drugs Fut. 22:1997;63.
10. Royce C. Drugs Fut. 18:1993;599.
11. Holland H.L., Kumaresan S., Tan L., Nzar V.C.O. J. Chem. Soc. Perkin Trans. 1. 13:1992;585-587.
12. Meegan M.J., Hughes R.B., Lloyd D.G., Williams D.C., Zisterer D.M. J. Med. Chem. 44:2001;1072-1084.
13. Goss P.E., Strasser K. Drugs. 62:2002;957-966.
14. Seraloni G.-E., Moslemi S. Mol. Cell. Endocrinol. 178:2001;117-131.
15. Dowsett M., Pfister C., Johnson S.R. Clin. Cancer Res. 5:1999;2338-2343.
16. Hershberg E.B. J. Org. Chem. 13:1948;542-546.
17. Mazur R.H. J. Org. Chem. 28:1963;248-250.
18. Regan B.M., Hayes F.N. J. Am. Chem. Soc. 78:1956;639-643.
19. Boyd M.R., Paull K.D. Drug Dev. Res. 34:1995;91-109.
20. Alley M.C., Scudiero D.A., Monks P.A., Hursey M.L., Czerwinski M.J., Fine D.L., Abbott B.J., Mayo J.G., Shoemaker R.H., Boyd M.R. Cancer Res. 48:1988;589-601.
21. Hellingshead M., Alley M.C., Camalier R.F., Abbott M.J., Mayo J.G., Malspeis L., Grever M.R. Life Sci. 57:1995;131-141.
22. Frank J.V., Tavares R.F., Ellis C.A. J. Pharm. Sci. 58:1969;138-140.